Compare PRE & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRE | AMRN |
|---|---|---|
| Founded | 2014 | 1989 |
| Country | Hong Kong | Ireland |
| Employees | 285 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.3M | 304.3M |
| IPO Year | N/A | 1998 |
| Metric | PRE | AMRN |
|---|---|---|
| Price | $15.47 | $14.43 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 2 | 1 |
| Target Price | ★ $30.50 | $12.00 |
| AVG Volume (30 Days) | ★ 176.0K | 78.5K |
| Earning Date | 06-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | $108.69 | N/A |
| Revenue Next Year | $58.68 | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $6.15 | $11.03 |
| 52 Week High | $23.63 | $20.90 |
| Indicator | PRE | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 47.80 |
| Support Level | $14.67 | $13.55 |
| Resistance Level | $17.76 | $16.91 |
| Average True Range (ATR) | 1.28 | 0.66 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 12.64 | 59.92 |
Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.